BERLIN, June 8, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that data from preclinical and clinical studies of the new lupus drug candidate, epratuzumab – a humanized anti-CD22 antibody, will be presented at the 2012 annual Congress of the European League Against Rheumatism (EULAR) in Berlin, Germany. Our partner, UCB, is evaluating epratuzumab in two randomized, double blind, placebo-controlled Phase III EMBODY™ studies for the treatment of patients with moderate or severe lupus.
